• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Hemogenyx Pharmaceuticals Plc. (OP: HOPHF )

    0.0031 UNCHANGED
    Last Price Updated: 12:21 PM EDT, Aug 5, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 0
    Open 0.0031
    Bid (Size) N/A (0)
    Ask (Size) N/A (0)
    Prev. Close 0.0031
    Today's Range 0.0031 - 0.0031
    52wk Range 0.0031 - 0.0400
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Hemogenyx Pharmaceuticals PLC Announces Strategic Investment from Prevail Partners, LLC
    Via ACCESSWIRE
    Hemogenyx Pharmaceuticals PLC Announces Half-year Report
    Via ACCESSWIRE

    Performance

    YTD
    N/A
    N/A
    1 Month
    N/A
    N/A
    3 Month
    N/A
    N/A
    6 Month
    -92.25%
    -92.25%
    1 Year
    N/A
    N/A

    More News

    Read More
    Hemogenyx Pharmaceuticals PLC - FLT3 Assay Ready for Phase I Trials at MD Anderson
    Via ACCESSWIRE
    Hemogenyx Pharmaceuticals PLC Announces CDX Development Update
    Via ACCESSWIRE
    Hemogenyx Pharmaceuticals PLC Announces Presentation at CBD S&T Conference
    Via ACCESSWIRE
    Hemogenyx Pharmaceuticals PLC Announces Macrophage-Directed Therapies Summit Presentation
    Via ACCESSWIRE
    Hemogenyx Pharmaceuticals PLC Announces Operations Update
    Via ACCESSWIRE
    Hemogenyx Pharmaceuticals PLC Announces CBR Brain Delivery
    Via ACCESSWIRE
    Hemogenyx Pharmaceuticals PLC Announces CBR Intranasal Delivery
    Via ACCESSWIRE
    Hemogenyx Pharmaceuticals PLC Announces FDA Consents to Phase I Trials of HEMO-CAR-T
    Via ACCESSWIRE
    Hemogenyx Pharmaceuticals PLC Announces Result of Annual General Meeting
    Via ACCESSWIRE
    Hemogenyx Pharmaceuticals PLC Announces Final Results
    Via ACCESSWIRE
    Hemogenyx Pharmaceuticals PLC Announces Total Voting Rights
    Via ACCESSWIRE
    Hemogenyx Pharmaceuticals discusses successful £3.5M capital raise as it advances HEMO-CAR-T program
    Via News Direct
    Hemogenyx Pharmaceuticals discusses successful £3.5M capital raise as it advances HEMO-CAR-T program
    Via TheNewswire.com
    Hemogenyx Pharmaceuticals PLC Announces the Approval and Issuance of U.S. Conditioning Patent
    Via ACCESSWIRE
    Hemogenyx Pharmaceuticals PLC Announces Submission of Complete Response to Clinical Hold
    Via ACCESSWIRE
    Hemogenyx Pharmaceuticals PLC Announces CBR Expanded to Treatment of Cancer
    Via ACCESSWIRE
    Hemogenyx Pharmaceuticals PLC Announces Lentivirus Re-manufacturing Completed
    Via ACCESSWIRE
    Hemogenyx Pharmaceuticals PLC Announces Placing to Raise US$4.2 million
    Via ACCESSWIRE
    Hemogenyx Pharmaceuticals PLC Announces HEMO-CAR-T Process Qualification Run Completed
    Via ACCESSWIRE
    Hemogenyx Pharmaceuticals PLC Announces Placing to Raise £534,375
    Via ACCESSWIRE
    Hemogenyx Pharmaceuticals PLC Announces Strategic Investment from Prevail Partners, LLC
    Via ACCESSWIRE
    Hemogenyx Pharmaceuticals PLC - Clinical Hold Lift Plan is accepted by FDA
    Via ACCESSWIRE
    Hemogenyx Pharmaceuticals PLC Announces CBR Patent Application Update
    Via ACCESSWIRE
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.